Patent · US Active

Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof

US10844045B2 · kind B2 · utility

0Cited by

0References

23Claims

0Family size

Assignee

BETA PHARMA, INC. · US

Inventors

Michael N. Greco · Lansdale, US
Michael John Costanzo · Bonney Lake, US
Michael Alan Green · Easton, US
Jirong Peng · Mequon, US
Victoria Lynn Wilde · Montclair, US
Don Zhang · Princeton, US

Key dates

Filing date	Jun 16, 2017
Grant date	Nov 24, 2020
Priority date	—
Expiry date	Jul 29, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Crystalline forms of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (1) and its pharmaceutically acceptable salts and compositions thereof useful for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.